Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.81 |
| ▸ | HTR2B | P41595 | 4/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | CD44 | P16070 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14861358 | 0.88 | HTR2C (0.81) | HTR2CHTR2BHTR7AADATHTR1A | |
| SCHEMBL24507078 | 0.86 | HTR2C (0.64) | HTR2CHTR2BAADATSIGMAR1 | |
| SCHEMBL20319013 | 0.76 | HTR2C (0.48) | HTR2CHTR2BHTR2APNMTCD44 | |
| SCHEMBL29935595 | 0.74 | HTR2C (0.46) | HTR2CHTR2BAADATHTR2APNMT | |
| SCHEMBL24507024 | 0.73 | L3MBTL1 (0.51) | HTR2CSIGMAR1 | |
| SCHEMBL19005683 | 0.73 | HTR2C (0.44) | HTR2CHTR2BPNMTCD44MAOB | |
| SCHEMBL24506896 | 0.72 | HTR2C (0.47) | HTR2C | |
| SCHEMBL24507023 | 0.72 | HTR2C (0.47) | HTR2C | |
| Hydrochloric Acid SCHEMBL28377835 | 0.72 | HTR2C (0.43) | HTR2CHTR2BPNMTCD44MAOB | |
| SCHEMBL29795113 | 0.71 | HTR2C (0.47) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2022-05-31 | — | — | US | disclosed |
| US-20210009607-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2021-01-14 | — | — | US | disclosed |
| US-10870660-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | HTR2C 104/4885HTR2B 91/4885HTR7 634/4885 |
| US-10870660-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | HTR2C 104/4885HTR2B 91/4885HTR7 634/4885 |
| US-20210009607-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | HTR2C 104/4885HTR2B 91/4885HTR7 634/4885 |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | HTR2C 104/4885HTR2B 91/4885HTR7 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.